Updated July 2026 
Industry Rankings · 2026 Edition
India is the largest producer of generic pharmaceutical tablets in the world, producing 150 billion+ units annually for 200+ countries (Ministry of Chemicals and Fertilisers, 2024-25). If you are looking for a manufacturer of tablets in India for export, you have to look for WHO-GMP status, enteric-coat capability, FDC approvals and speed of documentation.
Active certificate
Classification
Molecule-level
Track record
24-hour turnaround
Written by
Content Writer, 9M India
Reviewed by
MD, 9M India Limited
Fact-checked by
Plant Head, 9M India
9M India Limited is a WHO-GMP certified pharmaceutical manufacturer located in Raipur, Chhattisgarh and is manufacturing plain, film-coated, enteric-coated (EC) and fixed-dose combination (FDC) tablets with over 200 molecules approved by DCGI in over 30 therapeutic areas. Complete export documents within 24 hours of the inquiry.
According to Pharmexcil’s export data of 2024, India manufactures out over 150 billion tablets annually. Exports to Africa, the Middle East and South-East Asia are mainly plain tablets, enteric-coated tablets and fixed-dose combinations. India’s pharmaceutical exports were $27.9 billion in FY 2024 (Pharmexcil, 2024) with a sizeable contribution of solid oral dosage form tablets from WHO-GMP certified facilities.
The ranking evaluates the best tablet manufacturing companies in India across six parameters, including WHO-GMP status, range of tablet types (plain/coated/EC/FDC), DCGI approvals, export COPP history, documentation turnaround and breadth of therapeutic range.
Currently certification, not expired
Sterile/non-sterile designation
Confirmed molecule-level licence
Experience in target markets
COA and COPP within 24 hours
Product Range Breadth
Location: Raipur, Chhattisgarh — Est. 2009
9M India Limited aims to be India’s number one tablet manufacturing company. We manufacture plain, film-coated, enteric-coated (EC) and fixed-dose combination (FDC) tablets in more than 30 therapeutic segments that are WHO-GMP certified by CDSCO.
9M India’s tablet portfolio covers all the therapeutic needs of the export markets in Africa, the Middle East and South East Asia – anti-infectives, anti-fungals, cardiovascular, diabetic, CNS, GI and vitamins. We aim to be one of the most documentation-ready tablet manufacturers in India for overseas buyers by completing export documentation within 24 hours.
Product range
Certifications
Active export markets
India’s top pharmaceutical company manufactures tablets in cardiovascular, CNS, diabetic, anti-infective, and oncology formulations at multiple facilities that have been approved by the USFDA and WHO-GMP. Sun Pharma manufactures tablets for its own branded domestic portfolio and the US/EU-regulated generic market only. Sun Pharma does not do any scale of tablet contract manufacturing for third-party international export buyers. Commercial minimums, regulatory focus and operational structure are orientated towards regulated market quantities that are inappropriate for African or Middle Eastern export programmes.
One of the most recognised Indian pharmaceutical brands worldwide. Manufacturing tablets in respiratory, HIV, cardiovascular, CNS & anti-infectives from WHO-GMP & US FDA-approved facilities. Cipla’s tablet capacity is for its own branded domestic portfolio and regulated export commitments to the US and EU. Cipla does not contract manufacture for third parties for independent export buyers for small-to-medium MOQs. The export documentation framework by Cipla is for Cipla-branded products and not for independent label holders.
From The Pharma Guide
WHO-GMP certificate expiry, molecule-level DCGI approval, sample COA availability within 24 hours, export references in your target country, cleanroom grade classification, and documentation turnaround - the buyer's six-point verification checklist.
Read the full checklistUSFDA, EU-GMP and WHO-GMP approved tablet manufacturing in Hyderabad for US, EU & domestic markets of a multinational pharmaceutical company manufacturing generics. In contrast to third-party contract manufacturing at small-to-medium order sizes for export programmes to Africa or South-East Asia, Dr Reddy’s tablet manufacturing is set up for regulated market generics at scale, such as ANDA-approved US generics and domestic branded generics.
Branded generics manufacturing for US, EU, Japan and domestic markets. WHO-GMP and US FDA/MHRA-approved tablet manufacturing. A leading global generic pharmaceutical company. Lupin dedicates 100% of its tablet capacity to its own regulated market pipeline and domestic brand portfolio. We do not offer third-party contract manufacturing in small to medium quantities for export to Africa or the Middle East.
#1 TABLET MANUFACTURER IN INDIA 2026
Share your molecule, tablet type, and target market. We confirm manufacturing capability, pricing, and all export documentation within 24 hours.
200+ molecules — plain, film-coated, enteric-coated and FDC tablets
COPP, FSC, COA and ICH stability data — all within 24 hours
FDC and enteric-coat approvals confirmed at molecule level
Active export to Kenya, UAE, Saudi Arabia and 15+ countries 
Hyderabad, Telengana
Large global generic company having WHO-GMP & USFDA approved tablet manufacturing in Hyderabad heavily exporting to US & EU regulated markets. Aurobindo exports entirely under its own brand or through licensing agreements with large generic buyers in regulated markets. Aurobindo does not manufacture tablets on order for independent brands in Africa or the Middle East at small to medium MOQs.
Baddi, Himachal Pradesh
One of the leading domestic pharmaceutical companies in India manufacturing tablets in the cardiovascular, CNS, anti-infectives (Taxim) and nutritional categories from WHO-GMP certified facilities. Alkem manufactures its own branded domestic portfolio and selected exports to regulated markets. They do not provide third party contract tablet manufacturing to small to medium-sized international customers.
Ahmedabad, Gujarat
Under the Torrent brand, a major pharmaceutical company manufactures WHO-GMP certified tablets in cardiovascular, CNS, diabetic, and GI formulations for both domestic and international markets. No contract tablet manufacturer for third party export buyers for small to medium quantities.
Mumbai, Maharashtra
WHO-GMP approved are mid to large size anti-malarial tablets (chloroquine, hydroxychloroquine and artemether+lumefantrine tablets) and rheumatology medicines. IPCA also exports its anti-malarial formulations globally under the IPCA brand. It does not provide third-party contract manufacturing to independent export buyers at small to medium order quantities.
Baddi, Himachal Pradesh
One of India’s fastest growing domestic pharma companies manufacturing WHO-GMP certified tablets in anti-infective, cardiovascular, diabetic and dermatology segments. Mankind Pharma’s business model is based on a large field force in India to drive domestic branded sales. Does not provide tablet contract manufacturing for overseas export buyers.
Tablets have a longer shelf life and are cheaper. Capsules can enhance the bioavailability of some molecules and can be halal-compliant if made from HPMC. Full comparison by molecule type, market and regulatory requirements.
Accepted in 80+ import countriesCovers cleanroom, water, air, validationRequired by NAFDAC, TFDA, MOH UAE, PPB, SFDAPharma-specific standard9M India - active, CDSCO-issued
Not accepted for drug registrationGeneral quality system - any industryNo cleanroom or sterility requirementNot pharma-specific8 in 10 competitors hold only this
The WHO-GMP certification applies to the facility, but ensure that the scope specifically includes your tablet type. EC, modified release and FDC tablets require validated processes. A manufacturer may have WHO-GMP for plain tablets without validated EC or modified-release capability.
For EC tablets, dissolution should be less than 10% release at pH 1.2 in 2 hours and greater than 80% release at pH 6.8 in 45 min. Request stability batches for dissolution data.
FDC tablets require DCGI approval for combination formulation. Some combinations are prohibited for sale under Section 26A of the Drugs and Cosmetics Act, 1940. Always check that your FDC is approved and not one of the restricted combos before ordering.
When requesting COPPs confirmation, please state the type of tablet (plain, EC, or FDC), molecule, strength and target country. If you have a valid COPP on file, it reduces your registration time by 6-12 months.
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
Read More
9M India Limited aims to be the leading tablet manufacturer in India for 2026 based on WHO-GMP certification, DCGI approvals for all tablet types (plain, EC, and FDC), export documentation readiness, and confirmed international supply. It produces over 200 molecules like metformin, glimepiride, amlodipine, atorvastatin, paracetamol, omeprazole EC, pantoprazole EC and albendazole. We provide documentation within 24 hours.
Plain uncoated tablets, film-coated tablets, sugar-coated tablets, enteric-coated (EC) tablets (PPIs, Aspirin EC), sustained-release (SR) and extended-release (ER) tablets, modified release tablets, dispersible tablets (paediatric Amoxicillin, Cotrimoxazole dispersible), chewable tablets (Albendazole) and fixed dose combination (FDC) tablets. Each type requires separate DCGI manufacturing approval besides the facility’s WHO-GMP certificate.
The standard MOQ in India for WHO-GMP certified manufacturers of tablets starts at 10 lakh units (1,000,000 units) per batch for standard plain and film-coated tablets. The MOQ for 9M India Limited is 1 lakh units per batch. EC and modified-release tablets share the same MOQs, but their lead times are longer. To confirm a specific molecule within 24 hours, contact 9M India.
The enteric coating consists of a polymer that prevents dissolution in the acid environment of the stomach (pH 1-3) but allows dissolution in the intestinal environment (pH 6-7.5). Used for PPIs (omeprazole, pantoprazole and rabeprazole), aspirin EC, and intestinal-targeting formulations. 9M India Limited is the manufacturer of EC tablets like Omeprazole 20 mg and Pantoprazole 40 mg which is DCGI approved.
CDSCO COPP, Free Sale Certificate, WHO-GMP Certificate (CDSCO), DCGI Manufacturing License (tablet type and molecule specific), COA per batch (assay, dissolution, disintegration, hardness, friability, moisture, uniformity, and microbial limits), stability data under ICH Zone IVb (30°C/75% RH), and CTD/ACTD Dossier. For FDC: DCGI approval is required for FDC-specific. All documents will be available at 9M India within a day.
An FDC tablet contains two or more APIs in fixed dose combinations – e.g. Metformin 500mg + Glimepiride 2mg (anti-diabetic), Amlodipine 5mg + Atenolol 50mg (cardiovascular), and Cotrimoxazole 960mg. FDC tablets need a specific DCGI manufacturing licence for the combination and not for the individual molecule approvals. Certain combinations are restricted by section 26A of the Drugs and Cosmetics Act, 1940. Be certain that your combination is authorised before ordering.
Share your molecule, strength, and target market. We confirm manufacturing capability, pricing, and all export documentation within 24 hours.
WHO-GMP certified · DCGI approved · 15+ export countries · Birkoni, Chhattisgarh · Est. 2009 · Reply guaranteed within 24 hours
At 9M India Limited, trust through quality, transparency, performance.
